Through the beginning of December, private biotech firms had raised nearly $3.5 billion in 2005, according to Windhover's Strategic Intelligence Systems. So far this year, VCs have spread their money relatively evenly across the private life cycle, with A rounds brining in about $850 million, B rounds $900 million, C rounds $800 million and D rounds nearly $1 billion.
These numbers contrast starkly with 2004, when a similar peak at early trends in the year's private financing showed venture...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?